Related Experiment Video
Updated: Apr 16, 2026

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Identification of pathological CD133+ endothelial cells in venous malformations
Carrie J Shawber1,2, Averill Clapp2, Noa Shapiro-Franklin2
1Division of Reproductive Sciences, Department of Ob/Gyn, Columbia University Irving Medical Center Vagelos College of Physicians & Surgeons, and New York Presbyterian/Morgan Stanley Children's Hospital, New York, NY, United States.
Introduction:
Venous malformations (VMs) are congenital malformations of the venous system. Histologically, they are composed of dilated vascular channels. Prior studies have demonstrated that CD31 + endothelial cells (ECs) in VMs have pathogenic variants. Recent studies by our group found that the EC progenitor marker, CD133+, was expressed on VM endothelium in patient tissues. We hypothesized that a CD133+ VM endothelial cells contributes to VM pathobiology.
Methods:
VM cells were isolated from resected venous malformation tissues or fluid using CD133 as a marker. Isolated VM populations were characterized by quantative RT-PCR, fluorescence-activated cell sorting (FACS) and immunofluorescence staining (IF) for the expression of progenitor and mature EC genes/proteins. Cells underwent whole exome sequencing (WES) to probe for genetic variants. AKT and ERK activation status was assessed by Western blot and IF, and cell proliferation determined. Isolated CD133+ cells were xenografted in mice and their ability to recapitulate VM phenotype was assessed by histological analysis, IF and colormetric staining.
Results:
CD133+ cells isolated from VMs expressed progenitor and mature EC genes and proteins, and we termed them CD133+ VM endothelial cells (CD133+ VMECs). WES revealed CD133+ VMECs had pathogenic variants and variants of uncertain significance in genes reported in VMs, PIK3CA and TEK. CD133+ VMECs had increase proliferation and a subset had increase nuclear phospho-AKT. When implanted into a xenograft model, CD133+ VMECs with PIK3CA and TEK variants recapitulated clinical VM phenotypes.
Conclusion:
We have identified a novel cell type in VMs, CD133+ VMECs that express EC progenitor proteins, demonstrating incomplete or misdirected differentiation down the EC lineage and are capable of recapitulate the phenotype in a mouse model.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Regulation of Angiogenesis and Blood Supply

